Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The National Health Service named Oxford Vaccine Group’s Meningitis B vaccination programme one of the 70 most transformative discoveries over the past 70 years.

July 2018 marks the 70th birthday of the National Health Service. As part of the celebrations, the NHS’s I Am Research campaign highlights the research achievements that have improved health and care over the past 70 years, and shows how the work of National Institute for Health Research is helping to shape the future. Drawing on suggestions of experts from across the NIHR, the campaign presents 70 discoveries that have been the most transformative for both the NHS and its patients.

The Department of Paediatrics is very pleased that the Meningitis B vaccination programme featured among the 70 discoveries – particularly since the Oxford Vaccine Group administered the very first paediatric dose of the vaccine!

Meningococcal disease is caused by the bacterium Neisseria meningitidis, and can lead to meningitis (inflammation of the membranes that surround the brain) and septicaemia (blood poisoning). Meningitis B accounts for about 90% of meningococcal infections in the UK, each year there are between 500 and 1700 cases. It can affect all age groups, but the rates of disease are highest in children under five years of age, and most cases are seen in babies under the age of one. It is also often seen in teenagers aged between 15 and 19.

Introduction of the Meningitis B vaccination programme has seen cases in infants aged one or less drop by 42%. Currently Oxford Vaccine Group is leading another a study aimed at an older age group, investigating whether giving a MenB vaccine to teenagers reduces carriage of this bacteria, potentially providing protection to all ages from this dangerous infection.

If you would like to take part in the Be on the TEAM (TEenagers Against Meningitis) study, please take a look at the project website.

 

Similar stories

Increasing vaccine uptake among ethnic minorities

COVID-19 Public Engagement

Dr Samantha Vanderslott and Dr Seilesh Kadambari discuss their collaborative approach to providing ethnic minority groups with information on vaccines.

COVID-19: how to tackle vaccine hesitancy among BAME groups

COVID-19 Public Engagement

Samantha Vanderslott, Andrew Pollard and Seilesh Kadambari discuss vaccine uptake among Black, Asian and minority ethnic communities in an article for The Conversation.

Oxford University extends COVID-19 vaccine study to children

COVID-19 Research

The University of Oxford, together with three partner sites in London, Southampton and Bristol, is to launch the first study to assess the safety and immune responses in children and young adults of the ChAdOx1 nCoV-19 coronavirus vaccine.

World Health Organization experts provide guidance on use of the Oxford vaccine

COVID-19 Research

WHO SAGE says Oxford's coronavirus vaccine is safe and likely to be efficacious in older adults, and recommends its use in this age group.

Oxford leads first trial investigating dosing with alternating vaccines

COVID-19 Research

The Oxford Vaccine Group is to lead the first trial to explore alternating different COVID-19 vaccines, to explore the potential for flexibility in delivery and look for clues as to how to increase the breadth of protection against new virus strains.